Aevice Well being has introduced that its flagship medical gadget, a wearable stethoscope for respiratory well being monitoring, has been accepted by Singapore’s Well being Sciences Authority.
The AI-powered wearable stethoscope AeviceMD, which is worn on the chest, constantly detects and information irregular breath sounds, similar to wheezing, and displays important indicators together with coronary heart price and respiratory price.
Based mostly on a press assertion, the monitoring gadget system has been accepted to be used in individuals aged three and above and in each medical and residential settings.
WHY IT MATTERS
Singapore has one of many highest bronchial asthma and COPD prevalences on this planet. Bronchial asthma impacts round 5% of adults and 20% of youngsters within the nation whereas COPD is without doubt one of the 10 main illness killers.
With its distant well being monitoring know-how, Aevice Well being goals to assist cut back ED displays and readmissions amongst sufferers coping with these power respiratory illnesses. By offering well being professionals with an outline of a affected person’s lung well being, AeviceMD helps the early detection of potential exacerbations.
In keeping with the corporate, it should use its HSA approval as a springboard to increase the attain of its know-how to populations with excessive instances of respiratory illnesses.
“We’re excited to leverage Singapore’s strategic presence in Asia as a medical hub to deliver this novel know-how into new markets the place there’s a excessive prevalence of respiratory illnesses,” Aevice Well being CEO Adrian Ang shared.
THE LARGER TREND
The market approval comes two years since Aevice Well being first performed a medical trial of AeviceMD with the Nationwide College Well being System to research its use instances in paediatric sufferers with respiratory difficulties.
Apart from Singapore, the gadget has additionally been launched in Japan utilizing the $2 million proceeds from its pre-Sequence A funding spherical in 2021.